RHM is committed to bringing down the prices of therapies.
Why is this such a big deal?
There are two main reasons:
1. The value of working with a physician is that physician’s expertise, time, and advice (especially when this physician is also a medical advisor). The real value is the patient-physician relationship.
2. Prices are going to come down. One of the many great things about the emerging new medical economy is that it is NOT controlled by the insurance cartel, hospital systems, or big pharma.
The current average price for a 1cc treatment of stem cells or exosomes is about $4900. It costs manufacturers around $250 (but most likely less with efficient processes).
Manufacturers are selling their 1 cc product to distributors for between $600 and $1,500. The distributors then sell the product to Doctors for $1,500 to $2,000. Then the Doctors sell the products for $2,500 to $5,000. There are actually some Doctors charging as much as $12,000 per 1cc treatment. (It’s the sameproduct!)
By why is this a big deal? Everyone needs to get paid, right? Yes. If some group or person is adding value along the way from manufacturer to patient, they should be compensated.
However, let’s look at this example:
The average price for 30 capsules of Claritin is typically about $7.50. This is $90 for 365 day supply.
It is now possible to get a 365 day supply of Claritin for $54.99from a major drug store chain.
And, now, Amazon is selling a 365 day supply of Claritin for $10.99.
Whenever competition is involved, and there is a demand, prices come down.
There are more and more competitors coming into the market place.
Prices for ALL therapies, including regenerative therapies,WILL continue to come down. Doctors and distributors alike will have their “commissions” eliminated.
RHM is committed to making this happen.
There are two reasons:
1. Because it’s the right thing to do. No, we’re not socialists and want “medical care for all.” It’s quite the opposite. We believe strongly in the power of the free market.
2. The second reason is because of incentives. The data continues to show that there is a need for MORE treatments. “One and done” treatments rarely work. Since there is a need for more treatments, patients need to be incentived to do MORE treatments, and in order to do that, prices need to be lower than they are.